Screener
Aclaris Therapeutics ACRS Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 55,112 | 57,378 |
| Stockholders’ Equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 400,000,000 shares authorized at June 30, 2026 and December 31, 2025; 139,824,273 and 120,499,433 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid‑in capital | 1,133,997 | 1,070,255 |
| Accumulated other comprehensive (loss) income | (304) | 610 |
| Accumulated deficit | (1,009,113) | (967,784) |
| Total stockholders’ equity | 124,581 | 103,082 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's common stock?
- Aclaris Therapeutics (ACRS) reported common stock of $1K in Q2 2026.
- How has Aclaris Therapeutics's common stock changed year-over-year?
- Aclaris Therapeutics's common stock decreased by 0.0% year-over-year, from $1K to $1K.
- What is the long-term trend for Aclaris Therapeutics's common stock?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from $1K to $1K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Aclaris Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude